A double-blind, randomized, placebo-controlled crossover study to assess the efficacy of AST-120 in patients with gastroesophageal reflux disease (GERD) who continue to be symptomatic on a standard dose of proton pump inhibitor (PPI).

Trial Profile

A double-blind, randomized, placebo-controlled crossover study to assess the efficacy of AST-120 in patients with gastroesophageal reflux disease (GERD) who continue to be symptomatic on a standard dose of proton pump inhibitor (PPI).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2011

At a glance

  • Drugs Charcoal (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jun 2008 Actual patient number (4) added as reported by ClinicalTrials.gov.
    • 24 Jun 2008 The expected completion date for this trial has been changed from July 2008 to June 2008 as reported by ClinicalTrials.gov.
    • 24 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top